Yourgene Health Becomes a PacBio Compatible Partner: Enabling PacBio Customers to Optimise Size Selection for Long-Read Sequencing Libraries

Yourgene Health (part of the Novacyt group of companies), a leading international molecular diagnostics group, and PacBio, a leading developer of high-quality, highly accurate sequencing solutions, today announced a collaboration to optimise size selection for long-read sequencing workflows. PacBio has qualified Yourgene’s LightBench® instrument for size selection of long DNA fragments, enabling high yields for HiFi sequencing data.

Yourgene’s LightBench is an automated electrophoresis instrument, powered by Ranger® Technology. This platform uses a patent-protected, machine-vision algorithm to interpret and control gel electrophoresis in real time. It delivers accurate size selection for human genomic DNA and includes the ability to perform fragment length analysis for additional quality control.

PacBio HiFi sequencing is a single-molecule real-time (SMRT®) sequencing technology. It produces long (1,000 to 20,000+ bases), accurate reads with uniform genomic coverage and native methylation detection for use in applications such as whole genome reconstruction, haplotype phasing, detection of large and complex variants, and epigenetics.

A new Technical Note was released today for PacBio customers titled “Size selection of PacBio SMRTbell® libraries with the LightBench® instrument from Yourgene Health.” The Yourgene LightBench instrument is compatible with the Revio system. The automated LightBench workflow optimises walk away time, offering a scalable size selection solution for the preparation of PacBio SMRTbell sequencing libraries. Results from the initial study* assessing two fragment lengths in 84 human genomic DNA samples from frozen blood for library preparation showed consistent yields for 8 kb or 10 kb size and a zero percent failure rate.

Matthew Nesbitt, Co-Founder of Ranger Technology, at Yourgene Health, said: “PacBio HiFi sequencing technology is a game changer for whole genome applications. High-resolution size selection is crucial to maximising data yields from long-read sequencing and Yourgene is proud to offer researchers a precise and scalable solution with the LightBench.”

*Download the “Size selection of PacBio SMRTbell® libraries with the LightBench® instrument from Yourgene Health.” Technical Note to learn more: https://www.pacb.com/wp-content/uploads/Technical-note-Size-selection-of-PacBio-SMRTbell-libraries-with-the-LightBench-instrument-from-Yourgene-Health.pdf

Visit https://yourgenehealth.com/our-products/instruments/lightbench/ for further information about Yourgene’s LightBench instrument, and https://www.pacb.com/3rd-party-compatible-products/ for details of the PacBio Compatible programme.

Yourgene will also be attending the Association of Molecular Pathology (AMP) 2023 Annual Meeting & Expo in Salt Lake City, UT from 14–18 November. Visit booth #425 to learn more.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.